Clinical Trial Update: 506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma [NA]

View source ↗

Summary

Clinical trial update on the use of 506U78 for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma; the study status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• 506U78

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia, Lymphoma | NA | Status: COMPLETED